News/Events

Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) Thursday, July 24th, 2014

Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company’s KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company’s third IND to be allowed by the US FDA in the past 12 months.

Read more>

Kinex Pharmaceuticals Appoints Mr. Michael Murphy to the Board of Directors Tuesday, July 1st, 2014

Kinex Pharmaceuticals announced today that Dr. Jean-Pierre Sommadossi has elected to step down from the Board of Directors of Kinex but will continue to support the company as a Senior Advisor to the CEO. After an extensive search, the Board has appointed Michael P. Murphy to the Board of Directors to fill the Board seat vacated by Dr. Sommadossi.

Read more>

Hanmi Pharmaceuticals and Collaborative Partner Kinex Pharmaceuticals Report Encouraging Results on Oraxol® for Patients with Advanced Gastric Cancer from a Phase I/II Clinical Study Monday, June 30th, 2014

Hanmi Pharmaceuticals announces a positive study on Oraxol® use in a Phase I/II clinical proof-of-concept study (Study HM-OXL-201) of Oraxol – an oral form of the approved drug paclitaxel, with HM30181, a highly potent and selective, P-glycoprotein inhibitor of the gastro-intestinal tract. Read more>

Kinex Pharmaceuticals Inc. Announces Key Additions to Clinical Leadership Team in Newly Formed Clinical Development Office in Cranford, New Jersey Tuesday, May 13th, 2014

Kinex Pharmaceuticals announces the addition of two key executives to its clinical leadership team reporting to Chief Medical Officer, Dr. Rudolf Kwan. Douglas Kramer MD joins Kinex as Vice President of Clinical and Regulatory Affairs and Jane Devane has joined Kinex as Director of Clinical Operations. Read more>

Kinex Receives US FDA Allowance for Oratecan, an Oral Form of Irinotecan with Enhanced Gastrointestinal Absorption, the Second U.S. IND Based on the Orascovery Technology Platform Monday, May 5th, 2014

Kinex Pharmaceuticals, Inc. announced today that the United States Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for Oratecan, an oral form of an approved anti-cancer drug irinotecan with enhanced oral absorption. Read more>